Aileron Therapeutics, Inc. financial data

Symbol
ALRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
12407 N. Mopac Expy., Suite 250 #390, Austin, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 373 % -48.4%
Debt-to-equity 29.7 % +83%
Return On Equity -139 % -35.2%
Return On Assets -27.9 % +64.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.7M shares +377%
Common Stock, Shares, Outstanding 21.7M shares +377%
Entity Public Float 6.59B USD -65.6%
Common Stock, Value, Issued 108K USD +18.7%
Weighted Average Number of Shares Outstanding, Basic 21.7M shares +377%
Weighted Average Number of Shares Outstanding, Diluted 21.7M shares +377%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 12.9M USD +192%
General and Administrative Expense 16.7M USD +101%
Operating Income (Loss) -29.6M USD -116%
Net Income (Loss) Attributable to Parent -29.2M USD -126%
Earnings Per Share, Basic -3.16 USD/shares -11.3%
Earnings Per Share, Diluted -3.16 USD/shares -11.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD +46.3%
Cash, Cash Equivalents, and Short-term Investments 13.7M USD -57.8%
Other Assets, Current 755K USD
Assets, Current 18.7M USD +46%
Property, Plant and Equipment, Net 1K USD -96.6%
Operating Lease, Right-of-Use Asset 40K USD -73.7%
Intangible Assets, Net (Excluding Goodwill) 79.2M USD
Goodwill 6.33M USD
Other Assets, Noncurrent 2K USD
Assets 104M USD +713%
Accounts Payable, Current 1.08M USD +123%
Employee-related Liabilities, Current 1.45M USD +1311%
Liabilities, Current 5.66M USD +248%
Deferred Income Tax Liabilities, Net 3.33M USD
Other Liabilities, Noncurrent 116K USD
Liabilities 8.99M USD +453%
Accumulated Other Comprehensive Income (Loss), Net of Tax -26K USD
Retained Earnings (Accumulated Deficit) -310M USD -10.4%
Stockholders' Equity Attributable to Parent 6.89M USD -63%
Liabilities and Equity 104M USD +713%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.27M USD -13.1%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 100M shares +122%
Common Stock, Shares, Issued 21.7M shares +377%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.27M USD -304%
Deferred Tax Assets, Valuation Allowance 18.5M USD -76.1%
Deferred Tax Assets, Gross 31.8M USD -59%
Operating Lease, Liability 48K USD -70.4%
Depreciation 13K USD -13.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29.3M USD -128%
Lessee, Operating Lease, Liability, to be Paid 48K USD -72.7%
Property, Plant and Equipment, Gross 377K USD +10.9%
Operating Lease, Liability, Current 48K USD +45.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 48K USD +37.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -41.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 12.4M USD -80.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 59K USD +37.2%
Deferred Tax Assets, Net of Valuation Allowance 13.3M USD +82888%
Share-based Payment Arrangement, Expense 1.25M USD -6.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%